Eli Lilly stock closes at USD 1,181.89, up 2.68 percent at the closing bell
Published on 09/25/2026 at 19:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Eli Lilly and Co. closed at USD 1,181.89 on the NYSE on September 25, 2026, up USD 30.90 or 2.68 percent. The move followed FDA approval news for the company's once-weekly Onswik insulin injection, as Simply Wall St reported on September 25, 2026. Eli Lilly traded at USD 1,184.46 in after-hours trading at 4:15 p.m. ET, USD 2.57 or 0.22 percent above the NYSE close.
The session on September 25, 2026 in figures
Eli Lilly and Co. (ISIN US5324571083) opened at USD 1,156.67 after a previous close of USD 1,150.99. The shares reached a session low of USD 1,151.00 and a high of USD 1,197.79 before ending at USD 1,181.89. The closing level stood USD 15.90 below the high and USD 30.89 above the low.
The session volume was 2.42 million shares, below the reported average volume of 3.80 million. The close was 8.57 percent below the 52-week high of USD 1,292.65 and 65.04 percent above the 52-week low of USD 716.08. The share price therefore finished closer to the upper end of its annual range than to its lower boundary.
FDA approval and analyst actions support the shares
Onswik received US FDA approval as a once-weekly basal insulin for adults with type 2 diabetes, according to Simply Wall St. The approval added a dated company-specific development to the session's price backdrop. TD Cowen reiterated a Buy rating with a USD 1,250 target after approval, as Investing.com reported on September 22, 2026. Guggenheim had raised its target to USD 1,284 from USD 1,273 while retaining Buy, citing prescription trends and Zepbound formulary developments.
Berenberg upgraded Eli Lilly from Hold to Buy on September 15, 2026, and raised its target to USD 1,400 from USD 1,220. The firm cited returns on investment and growth in obesity treatment, according to MarketScreener. The health sector gained 0.65 percent in the market report carried by China Daily, while utilities and materials declined 1.02 percent and 1.01 percent.
Pharmaceutical peers and after-hours trading on September 25, 2026
Pfizer closed at USD 28.41, up 0.82 percent, while AbbVie gained 0.02 percent to USD 265.12. Merck closed at USD 147.98, down 0.07 percent, leaving Eli Lilly's 2.68 percent advance ahead of each cited peer. Eli Lilly's after-hours price was USD 1,184.46 at 4:15 p.m. ET, up 0.22 percent from the NYSE close.
EASD presentations begin on September 28, 2026
Eli Lilly is scheduled to present new cardiometabolic data at the European Association for the Study of Diabetes meeting from September 28 through October 2, 2026. The event covers data on Foundayo, retatrutide and eloratzep, according to MarketScreener. The presentations place new cardiometabolic trial data on the calendar for the next five trading days.
